The research team led by Lin Dongxin, Zheng Jian, and Wang Liqin from the Cancer Prevention and Treatment Center of Sun Yat-sen University and the National Key Laboratory of Malignant Tumor Prevention and Treatment in South China published a research paper titled “QDPR deficiency drives immune suppression in pancreatic cancer” in the Cell Metabolism journal. This study found that in pancreatic ductal adenocarcinoma (PDAC), quinone dihydropterin reductase (QDPR) deficiency…
PDAC
Scary! Pressure Will Accelerate The Occurrence of Malignant Pancreatic Cancer!
In a recent study published in the journal Cancer Cell, researchers from Columbia University Medical Center found that stress may accelerate the development of pancreatic cancer by stimulating the release of “fighting or running away” hormones, β-blockers that inhibit these hormones can effectively increase the survival of cancer-bearing mouse models. In addition, researchers analyzing patients with malignant pancreatic cancer found that patients taking selective β-blockers survived two-thirds more than the…
Effect of Deletion of Malic Enzyme for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas. PDAC is an aggressive and difficult malignancy to treat. Incidence of PDAC correlates with increasing age and therefore is an increasing problem as world population is aging. By 2030, researchers project that pancreatic cancer will become the 2nd leading cause of cancer related death in the US after lung cancer, surpassing colorectal, breast, and prostate cancer . Chromosomal…